← Research library

Pirabel during prolonged physical work and recovery — monograph section 6.2

Comparison in people · 2019

What was studied
78 healthy volunteers aged 18–25, divided into eight groups; six-hour physical-load model
Main finding
In 78 volunteers, Bemitil 250 mg and Pirabel retained 86.2% and 84.3% of baseline dynamic endurance, versus 68.1% with placebo. Volume II and the 2019 monograph report the same experiment.

Bemitil 250 mg · dynamic and grip endurance · 86.2% and 94% of baseline vs 68.1% and 63% with placebo · Both p<0.05 as marked

Related evidence maps: Sports performance ↗ · Military & occupational ↗

Reported findings and study design

78 healthy volunteers aged 18–25 in eight groups matched on initial performance and cardiorespiratory response. The monograph describes a double-blind six-hour strength-machine circuit, then three hours of recovery.

Population or model 78 healthy volunteers aged 18–25, divided into eight groups; six-hour physical-load model

Dose, route and schedule

The assigned dose was given immediately before the six-hour exercise circuit, four hours after it began and again one hour after it ended for the recovery comparison. Pirabel contained piracetam 600 mg and Bemitil 250 mg per administration. Route was not stated.

Protocol source ↗ · FMBA Volume II, printed pp. 214–219; matches methods in the 2019 monograph

Results · FMBA Volume II, printed pp. 214–219, Tables 46–47; methods match the 2019 Okovityi, Shustov and Bolotova monograph.
MeasureResultComparison, timing and statistics
Bemitil 250 mg · dynamic and grip endurance86.2% and 94% of baseline vs 68.1% and 63% with placeboBoth p<0.05 as marked
Pirabel · dynamic and grip endurance84.3% and 88% of baseline vs 68.1% and 63% with placeboBoth p<0.05 as marked
Bemitil 500 mg · dynamic and grip endurance72% and 70% of baselineOnly the static endurance comparison is marked significant in this arm.
Pirabel · three-hour dynamic recovery index1.52 ± 0.17 vs 1.00 ± 0.17 with placebop<0.01 as marked
Table 46 · performance after prolonged work (% of baseline)
Table 46 · performance after prolonged work (% of baseline)
Intervention per administrationPWC₁₇₀Dynamic enduranceStatic enduranceGrip endurance
Placebo6868.123.863
Bemitil 250 mg80*86.2*32.694*
Bemitil 500 mg747238.2*70
Piracetam 600 mg + Bemitil 250 mg7284.3*34.188*
Amtizol succinate 200 mg7372.838.4*65
Yakton 400 mg6573.445.4*90
Sydnocarb 10 mg6170.928.678
Eleutherococcus extract 5 mL7287.8*32.068

* p<0.05 versus placebo as marked. The narrative and table differ on some contrasts, including Pirabel static endurance.

Table 47 · three-hour recovery indices
Table 47 · three-hour recovery indices
InterventionDynamicStaticGripPWC₁₇₀
Placebo1.00 ± 0.170.43 ± 0.090.90 ± 0.100.03 ± 0.12
Bemitil 250 mg0.99 ± 0.130.54 ± 0.091.28 ± 0.17*0.52 ± 0.12**
Bemitil 500 mg1.50 ± 0.29**0.53 ± 0.110.76 ± 0.310.19 ± 0.25
Pirabel1.52 ± 0.17**0.31 ± 0.091.55 ± 0.21**0.42 ± 0.26*
Amtizol succinate1.19 ± 0.440.50 ± 0.130.76 ± 0.030.16 ± 0.26
Yakton1.17 ± 0.310.48 ± 0.130.72 ± 0.310.03 ± 0.25
Sydnocarb0.96 ± 0.110.33 ± 0.090.79 ± 0.060.24 ± 0.07*
Eleutherococcus1.12 ± 0.210.38 ± 0.120.76 ± 0.310.19 ± 0.18

M ± m as printed. * p<0.05, ** p<0.01 versus placebo.

Both monographs report the same 78-volunteer experiment. Arm sizes and allocation are unresolved. Without a piracetam-only arm, the study cannot establish a combination interaction in humans.

Source for these results ↗ · Reviewed 2026-11-17

Study limitations and source details

Study limitations

  • The individual group sizes, allocation and harms were not established.
  • No piracetam-only arm was included. The reported results cannot quantify synergy.

Related publications may describe some of the same participants or experiments.

Source details

Recovered monograph section

FMBA Volume II, printed pp. 214–219, Tables 46–47; methods match the 2019 Okovityi, Shustov and Bolotova monograph.

Section 6.2; allocation appraisal incomplete

Sources checked

Citation

Human comparative studyRussian-language source

S. V. Okovityi, E. B. Shustov, V. Ts. Bolotova. Pirabel during prolonged physical work and recovery — monograph section 6.2 Work Capacity, Fatigue, Correction. Knorus; section 6.2, pp. 184–189

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards